Pharmacogenomics: A Step forward Precision Medicine in Childhood Asthma

Genes (Basel). 2022 Mar 28;13(4):599. doi: 10.3390/genes13040599.


Personalized medicine, an approach to care in which individual characteristics are used for targeting interventions and maximizing health outcomes, is rapidly becoming a reality for many diseases. Childhood asthma is a heterogeneous disease and many children have uncontrolled symptoms. Therefore, an individualized approach is needed for improving asthma outcomes in children. The rapidly evolving fields of genomics and pharmacogenomics may provide a way to achieve asthma control and reduce future risks in children with asthma. In particular, pharmacogenomics can provide tools for identifying novel molecular mechanisms and biomarkers to guide treatment. Emergent high-throughput technologies, along with patient pheno-endotypization, will increase our knowledge of several molecular mechanisms involved in asthma pathophysiology and contribute to selecting and stratifying appropriate treatment for each patient.

Keywords: asthma; children; corticosteroids; genetics; leukotriene antagonists; pharmacogenomics; treatment; β2-agonists.

Publication types

  • Review

MeSH terms

  • Asthma* / diagnosis
  • Asthma* / drug therapy
  • Asthma* / genetics
  • Biomarkers
  • Child
  • Genomics
  • Humans
  • Pharmacogenetics*
  • Precision Medicine


  • Biomarkers